BioCentury
ARTICLE | Company News

Volition, ValiRx deal

October 18, 2010 7:00 AM UTC

ValiRx completed the previously announced sale of its Belgian cancer diagnostics subsidiary, ValiBIO S.A., to Volition for $400,000 in cash and $600,000 in Volition shares (see BioCentury, Oct. 4). ...